The Max Foundation and partner NGO Esperantra are pleased to announce they have signed a new MOU that will help patients in Peru gain access to treatment.
Esperantra, a non-profit organization working to reduce cancer mortality in Peru, has generously agreed to partner with The Max Foundation to facilitate the importation of medicines within Max Access Solutions.
“Esperantra and The Max Foundation are a perfect fit together,” said Inés García González, The Max Foundation’s Region Head for Latin America. “Our organizations have similar goals – expanding access to treatment, reducing cancer mortality, etc. – and Esperantra is a well-established organization in Peru with a great track record. We are honored to partner with them.”
Karla Ruiz de Castilla, Esperantra’s Executive Director, said: “It is our pleasure to partner with The Max Foundation and help expand access to treatment for patients in Peru. Together we are improving clinical outcomes and quality of life for people facing cancer.”
Thanks to the partnership with Esperantra, Peru has become the 70th country to have patients enrolled in Max Access Solutions.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
The Max Foundation is pleased to welcome Curt Malloy as the newest member of our Executive Board. Curt, a fellow advocate for people facing cancer around the world, has been a strong supporter of our work for many years throughout his active engagement in global health. Curt currently serves as the Chief Operating Officer at….
The Max Foundation CEO recognized for unwavering dedication to global, widespread health equity
The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer’s innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.
